Key Equity Analysts at Jefferies Maintained their ‘Buy’ rating for Karyopharm Therapeutics (NASDAQ:KPTI) Shares Today. Their PT Given is $19.0

September 17, 2017 - By Michael Collier

 Key Equity Analysts at Jefferies Maintained their ‘Buy’ rating for Karyopharm Therapeutics (NASDAQ:KPTI) Shares Today. Their PT Given is $19.0

Investors sentiment increased to 2.4 in 2016 Q4. Its up 0.88, from 1.52 in 2016Q3. It is positive, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.

Great West Life Assurance Can owns 1,658 shares. D E Shaw And reported 41,270 shares or 0% of all its holdings. Secor Capital Advsrs Limited Partnership reported 0.08% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Blackrock holds 0% or 4,156 shares in its portfolio. Dimensional Fund Advsr L P has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 556,383 were accumulated by Blackrock Institutional Trust Na. Jpmorgan Chase And has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Citadel Advisors has 45,984 shares for 0% of their portfolio. Blackrock Fund Advisors invested in 1.38M shares or 0% of the stock. Baker Bros Advisors L P has invested 0.02% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). The Florida-based State Board Of Administration Of Florida Retirement has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 17,859 are held by Credit Suisse Ag. Bank Of America Corp De accumulated 45,819 shares. Cam Grp A S has 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Palo Alto Lc owns 1.72% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 3.20 million shares.

Karyopharm Therapeutics (NASDAQ:KPTI) Rating Reaffirmed

The financial firm has just set a target price of $19.0 on Karyopharm Therapeutics (NASDAQ:KPTI) shares. This is 72.73 % from the current stock price. In a research note sent to investors on Monday, 11 September, Jefferies restate their Buy rating on shares of KPTI.

Investors sentiment increased to 2.4 in 2016 Q4. Its up 0.88, from 1.52 in 2016Q3. It is positive, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.

Great West Life Assurance Can owns 1,658 shares. D E Shaw And reported 41,270 shares or 0% of all its holdings. Secor Capital Advsrs Limited Partnership reported 0.08% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Blackrock holds 0% or 4,156 shares in its portfolio. Dimensional Fund Advsr L P has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 556,383 were accumulated by Blackrock Institutional Trust Na. Jpmorgan Chase And has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Citadel Advisors has 45,984 shares for 0% of their portfolio. Blackrock Fund Advisors invested in 1.38M shares or 0% of the stock. Baker Bros Advisors L P has invested 0.02% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). The Florida-based State Board Of Administration Of Florida Retirement has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 17,859 are held by Credit Suisse Ag. Bank Of America Corp De accumulated 45,819 shares. Cam Grp A S has 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Palo Alto Lc owns 1.72% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 3.20 million shares.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $23.64’s average target is 114.91% above currents $11 stock price. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Wednesday, September 9. The firm earned “Outperform” rating on Tuesday, August 11 by Leerink Swann. JP Morgan maintained it with “Overweight” rating and $19 target in Monday, March 14 report. The rating was upgraded by Jefferies to “Buy” on Tuesday, August 30. The firm earned “Hold” rating on Tuesday, March 15 by Jefferies. Jefferies maintained the shares of KPTI in report on Monday, September 11 with “Buy” rating. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Buy” rating given on Tuesday, December 22 by Canaccord Genuity. The rating was initiated by Raymond James with “Outperform” on Friday, May 27. MLV maintained the shares of KPTI in report on Wednesday, August 12 with “Buy” rating. H.C. Wainwright initiated the shares of KPTI in report on Thursday, August 18 with “Buy” rating.

The stock increased 4.07% or $0.43 on September 15, reaching $11. About 432,710 shares traded or 146.40% up from the average. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.

Analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report $-0.64 EPS on November, 6.They anticipate $0.05 EPS change or 7.25 % from last quarter’s $-0.69 EPS. After having $-0.64 EPS previously, Karyopharm Therapeutics Inc’s analysts see 0.00 % EPS growth.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $518.53 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

More notable recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” on June 30, 2017, also Fool.com with their article: “Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March” published on April 07, 2017, Seekingalpha.com published: “Karyopharm’s Selinexor Should Drive Substantial Growth” on March 27, 2017. More interesting news about Karyopharm Therapeutics Inc (NASDAQ:KPTI) were released by: Streetinsider.com and their article: “Karyopharm Therapeutics (KPTI) Names Michael Falvey as Chief Financial Officer” published on September 12, 2017 as well as Seekingalpha.com‘s news article titled: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q2 2017 Results …” with publication date: August 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.